title: Effect of spironolactone on renal prostaglandin excretion in patients with liver cirrhosis and ascites.
abstract: The effect of spironolactone on the urinary excretion of prostaglandins was studied in patients with liver cirrhosis and ascites. Patients were kept in bed and given a sodium-restricted diet for at least 4 days before spironolactone treatment was considered. Starting from the 5th day of protocol, patients were treated with this diuretic if their spontaneous weight loss had been less than 600 g during the 2 previous days. Patients were distributed in groups according to weight loss during the first 4 days on diuretic therapy: Group I (high responders), II (medium responders) and III (low responders). Group I patients showed higher basal values (4th day of protocol) of urinary sodium (P less than 0.02) and urinary 6-keto-PGF1 alpha (P less than 0.02) than the other patients, but there were no significant differences in the basal excretion rates of PGE2 nor TXB2 among the groups. The therapeutic requirement for spironolactone treatment in patients from Group I was delayed as compared with the other two groups (P less than 0.001) due to the fact that their spontaneous weight loss took place over a long period. For all patients, spironolactone administration produced a significant increase in 6-keto-PGF1 alpha excretion (P less than 0.01) without affecting significantly urinary elimination of PGE2 nor TXB2. A close relationship was found between the spironolactone-induced increments in urinary sodium and urinary 6-keto-PGF1 alpha excretion (r = 0.74, P less than 0.001). It is suggested that the ability of the kidney to synthetize prostacyclin can influence the natriuretic response to spironolactone therapy in patients with liver cirrhosis.
authors.forename: J F
authors.initials: JF
authors.lastname: Medina
authors.forename: J
authors.initials: J
authors.lastname: Prieto
authors.forename: F
authors.initials: F
authors.lastname: Guarner
authors.forename: J
authors.initials: J
authors.lastname: Quiroga
authors.forename: A
authors.initials: A
authors.lastname: Milazzo
mesh_terms: D015121:6-Ketoprostaglandin F1 alpha / Q000652:urine; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001201:Ascites / Q000652:urine*; D001835:Body Weight / Q000187:drug effects; D015232:Dinoprostone; D005260:Female; D006801:Humans; D007668:Kidney / Q000187:drug effects*; D008103:Liver Cirrhosis / Q000652:urine*; D008297:Male; D008875:Middle Aged; D011453:Prostaglandins / Q000652:urine*; D011458:Prostaglandins E / Q000652:urine; D012964:Sodium / Q000652:urine; D013148:Spironolactone / Q000494:pharmacology*; D013928:Thromboxane A2 / Q000652:urine
chemical_list: D011453:Prostaglandins; D011458:Prostaglandins E; D013148:Spironolactone; D013928:Thromboxane A2; D015121:6-Ketoprostaglandin F1 alpha; D012964:Sodium; D015232:Dinoprostone